Nature Medicine最新文献_第4页

Benchmark evaluation of DeepSeek large language models in clinical decision-making DeepSeek大型语言模型在临床决策中的基准评价

IF 82.9 1区医学

Nature Medicine Pub Date : 2025-04-23 DOI: 10.1038/s41591-025-03727-2

Sarah Sandmann, Stefan Hegselmann, Michael Fujarski, Lucas Bickmann, Benjamin Wild, Roland Eils, Julian Varghese

{"title":"Benchmark evaluation of DeepSeek large language models in clinical decision-making","authors":"Sarah Sandmann, Stefan Hegselmann, Michael Fujarski, Lucas Bickmann, Benjamin Wild, Roland Eils, Julian Varghese","doi":"10.1038/s41591-025-03727-2","DOIUrl":"https://doi.org/10.1038/s41591-025-03727-2","url":null,"abstract":"Large Language Models (LLMs) are increasingly transforming medical applications. However, proprietary models such as GPT-4o face significant barriers to clinical adoption because they cannot be deployed on site within healthcare institutions, making them non-compliant with stringent privacy regulations. Recent advancements in open-source LLMs such as DeepSeek models offer a promising alternative since they allow efficient fine-tuning on local data in hospitals with advanced IT infrastructure. To demonstrate the clinical utility of DeepSeek-V3 and DeepSeek-R1, we benchmarked their performance on clinical decision support tasks against proprietary LLMs, including GPT-4o and Gemini-2.0 Flash Thinking Experimental. Using 125 patient cases with sufficient statistical power, covering a broad range of frequent and rare diseases, we found that DeepSeek models perform equally well and in some cases better than proprietary LLMs. Our study demonstrates that open-source LLMs can provide a scalable pathway for secure model training enabling real-world medical applications in accordance with data privacy and healthcare regulations.","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"34 1","pages":""},"PeriodicalIF":82.9,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143862719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative benchmarking of the DeepSeek large language model on medical tasks and clinical reasoning DeepSeek 大型语言模型在医疗任务和临床推理方面的基准比较

IF 82.9 1区医学

Nature Medicine Pub Date : 2025-04-23 DOI: 10.1038/s41591-025-03726-3

Mickael Tordjman, Zelong Liu, Murat Yuce, Valentin Fauveau, Yunhao Mei, Jerome Hadjadj, Ian Bolger, Haidara Almansour, Carolyn Horst, Ashwin Singh Parihar, Amine Geahchan, Anis Meribout, Nader Yatim, Nicole Ng, Phillip Robson, Alexander Zhou, Sara Lewis, Mingqian Huang, Timothy Deyer, Bachir Taouli, Hao-Chih Lee, Zahi A. Fayad, Xueyan Mei

{"title":"Comparative benchmarking of the DeepSeek large language model on medical tasks and clinical reasoning","authors":"Mickael Tordjman, Zelong Liu, Murat Yuce, Valentin Fauveau, Yunhao Mei, Jerome Hadjadj, Ian Bolger, Haidara Almansour, Carolyn Horst, Ashwin Singh Parihar, Amine Geahchan, Anis Meribout, Nader Yatim, Nicole Ng, Phillip Robson, Alexander Zhou, Sara Lewis, Mingqian Huang, Timothy Deyer, Bachir Taouli, Hao-Chih Lee, Zahi A. Fayad, Xueyan Mei","doi":"10.1038/s41591-025-03726-3","DOIUrl":"https://doi.org/10.1038/s41591-025-03726-3","url":null,"abstract":"DeepSeek is a newly introduced large language model (LLM) designed for enhanced reasoning, but its medical-domain capabilities have not yet been evaluated. This study assessed the capabilities of three LLMs— DeepSeek-R1, ChatGPT-o1, and Llama 3.1-405B—in performing four different medical tasks: answering questions from the United States Medical Licensing Examination (USMLE), interpreting and reasoning based on text-based diagnostic and management cases, providing tumor classification according to RECIST 1.1 criteria, and providing summaries of diagnostic imaging reports across multiple modalities. In the USMLE test, the performance of DeepSeek-R1(accuracy=0.92) was slightly inferior to that of ChatGPT-o1(accuracy=0.95; p = 0.04) but better than that of Llama 3.1-405B (accuracy=0.83; p < 10-3). For text-based case challenges, DeepSeek-R1 performed similarly to ChatGPT-o1 (accuracy of 0.57 vs 0.55; p = 0.76 and 0.74 vs 0.76; p = 0.06, using New England Journal of Medicine and Medicilline databases, respectively). For RECIST classifications, DeepSeek-R1 also performed similarly to ChatGPT-o1 (0.73 vs 0.81; p = 0.10). Diagnostic reasoning steps provided by DeepSeek were deemed more accurate than those provided by ChatGPT and Llama 3.1-405B (average Likert score of 3.61, 3.22, and 3.13, respectively, p = 0.005 and p < 10−3). However, summarized imaging reports provided by DeepSeek-R1 exhibited lower global quality than those provided by ChatGPT-o1 (5-point Likert score: 4.5 vs 4.8; p < 10−3). This study highlights the potential of DeepSeek-R1 LLM for medical applications but also underlines areas needing improvements.","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"54 1","pages":""},"PeriodicalIF":82.9,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143862720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cognitive behavioral therapy skills via a smartphone app for subthreshold depression among adults in the community: the RESiLIENT randomized controlled trial 通过智能手机应用程序学习认知行为疗法技能，治疗社区成年人的阈值下抑郁症：RESiLIENT 随机对照试验

IF 82.9 1区医学

Nature Medicine Pub Date : 2025-04-23 DOI: 10.1038/s41591-025-03639-1

Toshi A. Furukawa, Aran Tajika, Rie Toyomoto, Masatsugu Sakata, Yan Luo, Masaru Horikoshi, Tatsuo Akechi, Norito Kawakami, Takeo Nakayama, Naoki Kondo, Shingo Fukuma, Ronald C. Kessler, Helen Christensen, Alexis Whitton, Inbal Nahum-Shani, Wolfgang Lutz, Pim Cuijpers, James M. S. Wason, Hisashi Noma

{"title":"Cognitive behavioral therapy skills via a smartphone app for subthreshold depression among adults in the community: the RESiLIENT randomized controlled trial","authors":"Toshi A. Furukawa, Aran Tajika, Rie Toyomoto, Masatsugu Sakata, Yan Luo, Masaru Horikoshi, Tatsuo Akechi, Norito Kawakami, Takeo Nakayama, Naoki Kondo, Shingo Fukuma, Ronald C. Kessler, Helen Christensen, Alexis Whitton, Inbal Nahum-Shani, Wolfgang Lutz, Pim Cuijpers, James M. S. Wason, Hisashi Noma","doi":"10.1038/s41591-025-03639-1","DOIUrl":"https://doi.org/10.1038/s41591-025-03639-1","url":null,"abstract":"Subthreshold depression, defined as a depressive status falling short of the diagnostic threshold for major depression, is common, disabling and constitutes a risk factor for future depressive episodes. Cognitive behavioral therapies (CBT) have been shown to be effective but are usually provided as packages of various skills. Little research has been done to investigate whether all their components are beneficial and contributory to mental health promotion. We addressed this issue by developing a smartphone CBT app that implements five representative CBT skills (behavioral activation, cognitive restructuring, problem solving, assertion training and behavior therapy for insomnia), and conducting a master randomized study that included four 2 × 2 factorial trials to enable precise estimation of skill-specific efficacies. Between September 2022 and February 2024, we recruited 3,936 adult participants with subthreshold depression. Among those randomized, the follow-up rate was 97% at week 6 and adherence to the app was 84%. The study showed that all included CBT skills and their combinations differentially beat all three control conditions of delayed treatment, health information or self-check, with effect sizes ranging between −0.67 (95% confidence interval: −0.81 to −0.53) and −0.16 (−0.30 to −0.02) for changes in depressive symptom severity from baseline to week 6, as measured with the Patient Health Questionnaire-9 scores. Knowledge of the active ingredients of CBT can better inform the design of more effective and scalable psychotherapies in the future. (UMIN Clinical Trials Registry UMIN000047124).","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"4 1","pages":""},"PeriodicalIF":82.9,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143862722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antisense oligonucleotide treatment in a preterm infant with early-onset SCN2A developmental and epileptic encephalopathy 反义寡核苷酸治疗早产儿SCN2A发育不全和癫痫性脑病

IF 82.9 1区医学

Nature Medicine Pub Date : 2025-04-22 DOI: 10.1038/s41591-025-03656-0

Matias Wagner, Géza Berecki, Walid Fazeli, Claudia Nussbaum, Andreas W. Flemmer, Silvana Frizzo, Farina Heer, Florian Heinen, Robert Horton, Henry Jacotin, William Motel, Brian Spar, Christoph Klein, Corinna Siegel, Christoph Hübener, Sophia Stöcklein, Marco Paolini, Martin Staudt, Moritz Tacke, Markus Wolff, Steven Petrou, Marcio Souza, Ingo Borggraefe

{"title":"Antisense oligonucleotide treatment in a preterm infant with early-onset SCN2A developmental and epileptic encephalopathy","authors":"Matias Wagner, Géza Berecki, Walid Fazeli, Claudia Nussbaum, Andreas W. Flemmer, Silvana Frizzo, Farina Heer, Florian Heinen, Robert Horton, Henry Jacotin, William Motel, Brian Spar, Christoph Klein, Corinna Siegel, Christoph Hübener, Sophia Stöcklein, Marco Paolini, Martin Staudt, Moritz Tacke, Markus Wolff, Steven Petrou, Marcio Souza, Ingo Borggraefe","doi":"10.1038/s41591-025-03656-0","DOIUrl":"https://doi.org/10.1038/s41591-025-03656-0","url":null,"abstract":"Early-onset SCN2A developmental and epileptic encephalopathy is caused by SCN2A gain-of-function variants. Here we describe the clinical experience with intrathecally administered elsunersen, a gapmer antisense oligonucleotide targeting SCN2A, in a female preterm infant with early-onset SCN2A developmental and epileptic encephalopathy, in an expanded access program. Before elsunersen treatement, the patient was in status epilepticus for 7 weeks with a seizure frequency of 20–25 per hour. Voltage-clamp experiments confirmed impaired channel inactivation and increased persistent current consistent with a gain-of-function mechanism. Elsunersen treatment demonstrated a favorable safety profile with no severe or serious adverse events reported after 19 intrathecal administrations over 20 months. After administration in combination with sodium channel blockers, status epilepticus was interrupted intermittently and ultimately ceased after continued dosing. A >60% reduction in seizure frequency corresponding to five to seven seizures per hour was observed, which has been sustained during follow-up until the age of 22 months. These data provide preliminary insights on the safety and efficacy of elsunersen in a preterm infant. Additional investigation on the benefits of elsunersen in clinical trials is warranted.","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"27 1","pages":""},"PeriodicalIF":82.9,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143858086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Microglia drive amyloid-β clearance in immunized patients with Alzheimer’s disease 小胶质细胞驱动阿尔茨海默病患者的淀粉样蛋白-β清除

IF 82.9 1区医学

Nature Medicine Pub Date : 2025-04-22 DOI: 10.1038/s41591-025-03677-9

引用次数: 0

Global, regional and national burden of dietary iron deficiency from 1990 to 2021: a Global Burden of Disease study 1990年至2021年膳食缺铁的全球、区域和国家负担：全球疾病负担研究

IF 82.9 1区医学

Nature Medicine Pub Date : 2025-04-22 DOI: 10.1038/s41591-025-03624-8

Sooji Lee, Yejun Son, Jiyoung Hwang, Min Seo Kim, Jae Il Shin, Dong Keon Yon, Nicholas. J. Kassebaum

{"title":"Global, regional and national burden of dietary iron deficiency from 1990 to 2021: a Global Burden of Disease study","authors":"Sooji Lee, Yejun Son, Jiyoung Hwang, Min Seo Kim, Jae Il Shin, Dong Keon Yon, Nicholas. J. Kassebaum","doi":"10.1038/s41591-025-03624-8","DOIUrl":"https://doi.org/10.1038/s41591-025-03624-8","url":null,"abstract":"Although iron deficiency is well documented, less is known about dietary involvement in symptomatic iron deficiency manifesting in medical conditions. In this study, we quantified the global burden of dietary iron deficiency, focusing on where inadequate dietary iron intake leads to clinical manifestations such as anemia. We analyzed data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 to estimate dietary iron deficiency prevalence and disability-adjusted life years (DALYs), stratified by age, sex, geography and socio-demographic index (SDI) across 204 countries. In 2021, global age-standardized prevalence and DALY rates were 16,434.4 (95% uncertainty interval (UI), 16,186.2–16,689.0) and 423.7 (285.3–610.8) per 100,000 population, with rates decreasing by 9.8% (8.1–11.3) and 18.2% (15.4–21.1) from 1990 to 2021. A higher burden was observed in female individual (age-standardized prevalence, 21,334.8 (95% UI, 20,984.8–21,697.4); DALYs, 598.0 (402.6–854.4)) than in male individual ((age-standardized prevalence, 11,684.7 (11,374.6–12,008.8); DALYs, 253.0 (167.3–371.0)). High-SDI countries presented greater improvement, with a 25.7% reduction compared to 11.5% in low-SDI countries. Despite global improvements, dietary iron deficiency remains a major health concern with a global prevalence of 16.7%, particularly affecting female individuals, children and residents in low-SDI countries. Urgent interventions through supplementation, food security measures and fortification initiatives are essential.","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"62 1","pages":""},"PeriodicalIF":82.9,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143858087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Blood pressure reduction and all-cause dementia in people with uncontrolled hypertension: an open-label, blinded-endpoint, cluster-randomized trial 降低未控制高血压患者的血压与全因痴呆症：一项开放标签、盲终点、分组随机试验

IF 82.9 1区医学

Nature Medicine Pub Date : 2025-04-21 DOI: 10.1038/s41591-025-03616-8

Jiang He, Chuansheng Zhao, Shanshan Zhong, Nanxiang Ouyang, Guozhe Sun, Lixia Qiao, Ruihai Yang, Chunxia Zhao, Huayan Liu, Weiyu Teng, Xu Liu, Chang Wang, Songyue Liu, Chung-Shiuan Chen, Jeff D. Williamson, Yingxian Sun

{"title":"Blood pressure reduction and all-cause dementia in people with uncontrolled hypertension: an open-label, blinded-endpoint, cluster-randomized trial","authors":"Jiang He, Chuansheng Zhao, Shanshan Zhong, Nanxiang Ouyang, Guozhe Sun, Lixia Qiao, Ruihai Yang, Chunxia Zhao, Huayan Liu, Weiyu Teng, Xu Liu, Chang Wang, Songyue Liu, Chung-Shiuan Chen, Jeff D. Williamson, Yingxian Sun","doi":"10.1038/s41591-025-03616-8","DOIUrl":"https://doi.org/10.1038/s41591-025-03616-8","url":null,"abstract":"Dementia is a leading cause of death and disability worldwide. Here we tested the effectiveness of blood pressure (BP) reduction on the risk of all-cause dementia among 33,995 individuals aged ≥40 years with uncontrolled hypertension in rural China. We randomly assigned 163 villages to a non-physician community healthcare provider-led intervention and 163 villages to usual care. In the intervention group, trained non-physician community healthcare providers initiated and titrated antihypertensive medications according to a simple stepped-care protocol to achieve a systolic BP goal of <130 mm Hg and a diastolic BP goal of <80 mm Hg, with supervision from primary care physicians. Over 48 months, the net reduction in systolic BP was 22.0 mm Hg (95% confidence interval (CI) 20.6 to 23.4; P < 0.0001) and that in diastolic BP was 9.3 mm Hg (95% CI 8.7 to 10.0; P < 0.0001) in the intervention group compared to usual care. The primary outcome of all-cause dementia was significantly lower in the intervention group than in the usual care group (risk ratio: 0.85; 95% CI 0.76 to 0.95; P = 0.0035). Additionally, serious adverse events occurred less frequently in the intervention group (risk ratio: 0.94; 95% CI 0.91 to 0.98; P = 0.0006). This cluster-randomized trial indicates that intensive BP reduction is effective in lowering the risk of all-cause dementia in patients with hypertension. ClinicalTrials.gov: NCT03527719.","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"47 1","pages":""},"PeriodicalIF":82.9,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143857369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between plausible genetic factors and weight loss from GLP1-RA and bariatric surgery 合理的遗传因素与GLP1-RA和减肥手术的体重减轻之间的关系

IF 82.9 1区医学

Nature Medicine Pub Date : 2025-04-18 DOI: 10.1038/s41591-025-03645-3

Jakob German, Mattia Cordioli, Veronica Tozzo, Sarah Urbut, Kadri Arumäe, Roelof A. J. Smit, Jiwoo Lee, Josephine H. Li, Adrian Janucik, Yi Ding, Akintunde Akinkuolie, Henrike O. Heyne, Andrea Eoli, Chadi Saad, Yasser Al-Sarraj, Rania Abdel-latif, Shaban Mohammed, Moza Al Hail, Alexandra Barry, Zhe Wang, Tatiana Cajuso, Andrea Corbetta, Pradeep Natarajan, Samuli Ripatti, Anthony Philippakis, Lukasz Szczerbinski, Bogdan Pasaniuc, Zoltán Kutalik, Hamdi Mbarek, Ruth J. F. Loos, Uku Vainik, Andrea Ganna

{"title":"Association between plausible genetic factors and weight loss from GLP1-RA and bariatric surgery","authors":"Jakob German, Mattia Cordioli, Veronica Tozzo, Sarah Urbut, Kadri Arumäe, Roelof A. J. Smit, Jiwoo Lee, Josephine H. Li, Adrian Janucik, Yi Ding, Akintunde Akinkuolie, Henrike O. Heyne, Andrea Eoli, Chadi Saad, Yasser Al-Sarraj, Rania Abdel-latif, Shaban Mohammed, Moza Al Hail, Alexandra Barry, Zhe Wang, Tatiana Cajuso, Andrea Corbetta, Pradeep Natarajan, Samuli Ripatti, Anthony Philippakis, Lukasz Szczerbinski, Bogdan Pasaniuc, Zoltán Kutalik, Hamdi Mbarek, Ruth J. F. Loos, Uku Vainik, Andrea Ganna","doi":"10.1038/s41591-025-03645-3","DOIUrl":"https://doi.org/10.1038/s41591-025-03645-3","url":null,"abstract":"Obesity is a major public health challenge. Glucagon-like peptide-1 receptor agonists (GLP1-RA) and bariatric surgery (BS) are effective weight loss interventions; however, the genetic factors influencing treatment response remain largely unexplored. Moreover, most previous studies have focused on race and ethnicity rather than genetic ancestry. Here we analyzed 10,960 individuals from 9 multiancestry biobank studies across 6 countries to assess the impact of known genetic factors on weight loss. Between 6 and 12 months, GLP1-RA users had an average weight change of −3.93% or −6.00%, depending on the outcome definition, with modest ancestry-based differences. BS patients experienced −21.17% weight change between 6 and 48 months. We found no significant associations between GLP1-RA-induced weight loss and polygenic scores for body mass index or type 2 diabetes, nor with missense variants in GLP1R. A higher body mass index polygenic score was modestly linked to lower weight loss after BS (+0.7% per s.d., P = 1.24 × 10−4), but the effect attenuated in sensitivity analyses. Our findings suggest known genetic factors have limited impact on GLP1-RA effectiveness with respect to weight change and confirm treatment efficacy across ancestry groups.","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"75 5 1","pages":""},"PeriodicalIF":82.9,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143846627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Helmholtz Health task force to strengthen prevention research and its translation globally 亥姆霍兹卫生工作队加强预防研究及其在全球的推广

IF 82.9 1区医学

Nature Medicine Pub Date : 2025-04-18 DOI: 10.1038/s41591-025-03590-1

{"title":"Helmholtz Health task force to strengthen prevention research and its translation globally","authors":"","doi":"10.1038/s41591-025-03590-1","DOIUrl":"https://doi.org/10.1038/s41591-025-03590-1","url":null,"abstract":"Prevention research aims to understand, mitigate and ultimately avert the onset and progression of disease and the spillover of pathogens. Such research includes the analysis of risk factors and fundamental mechanisms of disease emergence, early detection and screening, stratification into risk groups, and the development and evaluation of preventive interventions. In the face of population aging and escalating planetary health challenges, such as the climate crisis1, prevention research is crucial in mitigating the burden of both non-communicable and communicable diseases.In recognition of the importance of shifting from reactive medicine to preventative approaches, Helmholtz Health has put together a strategic task force dedicated to prevention research. The Helmholtz Association is the largest scientific organization in Germany and, with an annual budget of €5 billion, one of the leading intramural research programs in Europe. Its mission is to contribute to solving grand challenges faced by society, science and industry, by conducting research in six fields: aeronautics, space and transport; earth and environment; energy; health; matter; and information. Helmholtz Health represents six health research centers across Germany, with a workforce base of approximately 10,000 people, and the German National Cohort (NAKO)2. The Helmholtz Health Prevention Task Force comprises interdisciplinary experts from all six research centers and NAKO, covering a wide spectrum of health research areas that include infectious disease, cancer, and cardiovascular, metabolic, respiratory and neurodegenerative diseases. The task force has been tasked with outlining a strategic roadmap for strengthening prevention research and its translation globally.","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"27 1","pages":""},"PeriodicalIF":82.9,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143846592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Proteomics sheds light on unequal aging 蛋白质组学揭示了不平等衰老

IF 82.9 1区医学

Nature Medicine Pub Date : 2025-04-18 DOI: 10.1038/s41591-025-03657-z

Cecilia Potente

引用次数: 0